Clinical characteristics, in-hospital management and treatment at discharge
| Variables | Total population | Stroke | No stroke | p Value |
|---|---|---|---|---|
| Age (years) | 66.9±12.8 | 71.3±10.2 | 66.7±12.9 | <0.010 |
| Female sex | 27.9% | 33.2% | 27.6% | 0.101 |
| GRACE 6 months | 112.9±33.4 | 123.8±30.5 | 112.5±33.5 | <0.010 |
| CHA2DS2VASc | 2.7±1.9 | 3.4±1.8 | 2.6±1.8 | <0.010 |
| MDRD-4 (mL/min/1.73 m2) | 74.9±39.3 | 68.8±23.7 | 75.1±39.8 | 0.032 |
| TNI peak (ng/mL) | 28.9±123.8 | 20.8±40.6 | 29.3±126.2 | 0.366 |
| Hypertension | 57.1% | 66.3% | 56.7% | 0.010 |
| Diabetes | 26.5% | 35.9% | 26.0% | 0.003 |
| Hypercholesterolemia | 45.2% | 46.2% | 45.1% | 0.779 |
| Previous CAD | 23.1% | 29.9% | 22.8% | 0.026 |
| Previous stroke | 6.8% | 14.1% | 6.5% | <0.001 |
| Previos atrial fibrillation | 10.5% | 16.8% | 10.3% | 0.004 |
| Hospitalisation | ||||
| EF <40% | 12.8% | 14.1% | 12.7% | 0.576 |
| STEMI | 31.5% | 27.7% | 31.7% | 0.256 |
| Multivessel | 37.4% | 32.1% | 37.7% | 0.124 |
| PCI | 64.2% | 56.5% | 64.5% | 0.027 |
| At discharge | ||||
| Dual antiplatelet therapy | 71.1% | 65.2% | 71.3% | 0.074 |
| Warfarin | 7.4% | 10.9% | 7.2% | 0.062 |
| ACEI/A2 blocker | 60.3% | 60.3% | 60.3% | 0.999 |
| Statins | 83.3% | 79.3% | 83.5% | 0.141 |
| β-Blocker | 67.7% | 66.3% | 67.8% | 0.669 |
Values are n (%) or median (IQR).
MDRD-4, glomerular filtration rate calculated by MDRD Formula for glomerular filtration rate.
A2 blocker, angiotensin II receptor blocker; ACEI, ACE inhibitor; CAD, coronary artery disease; EF, ejection fraction; GRACE, Global Registry of Acute Coronary Events; MDRD, modification of diet in renal disease; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TNI, troponin.